Navigation Links
Master genetic switch found for chronic pain

In experiments with mice, researchers have found that eliminating what appears to be a master genetic switch for the development of pain-sensing neurons knocks out the animals' response to "neuropathic pain." Such pain is abnormal pain that outlasts the injury and is associated with nerve and/or central nervous system changes. The animals rendered deficient in the gene, called Runx1, also showed lack of response to discomfort caused by heat and cold and inflammation. The researchers said that their findings, reported in the February 2, 2006, issue of Neuron, could have implications for the design of improved pain therapies.

In their experiments, Qiufu Ma and colleagues studied the Runx1 gene because past research had shown it to code for a protein "transcription factor," which is a master regulator of multiple genes. Runx1 is one of a group of proteins that are key players involved in transmitting external sensory information, like pain and the perception of movement, to the spinal cord. In two other related papers in the same issue, Silvia Arber and colleagues and Tom Jessell and colleagues examine related aspects of the biological importance underlying the Runx transcription factors.

Runx1 was known to be expressed only in sensory nerve cells called "nociceptive" cells, involved in sensing pain. Such pain-sensing cells function by translating painful stimuli into nerve signals via specialized pores called "ion channels" in the neurons, as well as specialized receptors. The researchers' studies of Runx1 in these cells revealed that during embryonic development, the gene is characteristically expressed in pain-receptor cells involved in neuropathic pain. When they knocked out the gene, they found that the normal development of such specialized nerve cells was impaired. The animals had lost ion channels known to be involved in reacting to painful heat or cold, as well as those involved in pain due to damaged tissue. The researchers also found that th e Runx1-deficient animals showed deficient wiring of certain types of pain neurons.

In key experiments, the researchers measured the Runx1-deficient animals' response to four types of pain--thermal, mechanical, inflammatory, and neuropathic.

The researchers produced a pain response by subjecting the animals' hindpaw to either the cold of acetone or an uncomfortably warm plate (thermal); the uncomfortable prick of a filament (mechanical); an injection of an inflammation-inducing chemical (inflammatory); or nerve damage (neuropathic). They quantified the animals' response by measuring how long the animals lifted or licked their affected paw in response to the treatments.

Ma and his colleagues found that, while the deficient animals showed normal response to mechanical pain, they showed significantly lowered thermal, neuropathic, and inflammatory pain response.

The researchers concluded that while the diverse specialized components of the pain-sensing machinery could be established in a piecemeal fashion, "Our data, however, provide strong evidence that Runx1 is required to specify the receptive properties of a large cohort of nociceptive sensory neurons." They also concluded that the dual functions they discovered for Runx1--controlling specification of sensory neurons and regulating how they target their wiring--"form a genetic basis for the assembly of specific neural circuits for nociceptive information processing.

"Finally, the identification of a core transcriptional control program for many of the ion channels and receptors known to transduce noxious stimuli has intriguing implications for the design of more effective pain therapies," they wrote.


'"/>

Source:Cell Press


Related biology news :

1. Master gene controls healing of skin in fruit flies and mammals
2. Master regulatory gene found that guides fate of blood-producing stem cells
3. Master planners in brain may coordinate other areas roles in cognitive tasks
4. Master regulatory gene of epithelial stem cells identified
5. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
6. Scientists detect probable genetic cause of some Parkinsons disease cases
7. Mouse brain tumors mimic those in human genetic disorder
8. Scientists identify genetic pathways essential to RNA interference
9. Researchers trace evolution to relatively simple genetic changes
10. Key mechanism in genetic inheritance during cell division identified
11. Scientists identify genetic pathways essential to RNA interference
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a ... a new white paper " What You Should Know ... problem of ensuring user authenticity is a growing concern. ... authentication of users. However, traditional authentication schemes such as ... Biometric authentication offers an elegant solution to ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... , Feb. 16, 2017   Biostage, Inc. ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, announced today the closing on February ... 20,000,000 shares of common stock and warrants to purchase ... of $8.0 million. The offering was priced at $0.40 ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
Breaking Biology Technology: